Unorthodox therapy for murine neuroblastoma with 6-hydroxydopamine (NSC-233898), bretylium tosylate (NSC-62164), papaverine (NSC-35443), and butyric acid (NSC-8415).
D000818:Animals; D001949:Bretylium Compounds / Q000627:therapeutic use*; D001950:Bretylium Tosylate / Q000627:therapeutic use* / Q000633:toxicity; D002087:Butyrates / Q000627:therapeutic use* / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D006892:Hydroxydopamines / Q000627:therapeutic use* / Q000633:toxicity; D051379:Mice; D008805:Mice, Inbred A; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009447:Neuroblastoma / Q000188:drug therapy*; D010208:Papaverine / Q000627:therapeutic use* / Q000633:toxicity
D001949:Bretylium Compounds; D002087:Butyrates; D006892:Hydroxydopamines; D001950:Bretylium Tosylate; D010208:Papaverine